I. INTRODUCTION
Robustness against perturbations is important for the functioning of biological signaling networks (215) . We posit that gliotransmission contributes to making brain signaling robust. There is an emerging understanding of how the different types of glial cells interact with neurons to shape the information processing in the mature healthy brain, as well as of the importance for normal central nervous system (CNS) development and contribution to disease processes. These themes are the objectives of the present review.
The glia of the CNS was originally seen as "glue" keeping the nerve cell elements together and involved in various housekeeping functions. Rudolf Virchow , "the father of cellular pathology," called it "Nervenkitt" and coined the term neuroglia in 1856 translating the German term into the Greek (192) . [In singular, the words neuroglia or glia refer to the supportive part of the nervous tissue; in plural, the words refer to its cells (http://www.oed. com/view/Entry/126393#eid34669799).]
It soon became evident that glia comprise three types of cell: astrocytes/astroglia, microglia, and oligodendrocytes, which were all ascribed special functions in the brain. Astrocytes were shown to play various housekeeping roles for neurons, oligodendrocytes to make the myelin surrounding axons, and microglia to be activated by diverse noxious stimuli to the brain. In recent years, each of these types of glia has been demonstrated to participate much more directly in the function of neurons than previously thought. For a recent authoritative review on neuroglia, see the book edited by Kettenmann and Ransom (190) .
The term tripartite synapse was coined (12) to emphasize the direct participation of astroglia in synaptic signaling, along with the nerve ending and the postsynaptic part of the neuron. Even tiny microglial processes contact synapses (379) , and oligodendroglia have neurotransmitter receptors (186) . In addition to direct participation in synaptic signal transmission, through the release of "gliotransmitter," neuroglia perform multiple nurture activities essential for normal nervous system function (such as providing nutrients including energy substrates and transmitter precursors, re-moval of waste products). The proper control of these activities must rely on signal transmission, i.e., mutual exchange of information between neuron and glia, and on interaction with the body through the bloodstream. Here we review signaling to and from neuroglia, focusing on signals mediated by the gliotransmitters glutamate, GABA, ATP, D-serine, and L-lactate.
A. Neuroglia Numbers
The commonly held belief that neuroglial cells vastly outnumber neurons is misleading. In the grey matter of the human neocortex, glia-to-neuron ratios are ϳ1.5 as determined by stereological methods using morphological identification of cell types (325, 373) or by isotropic fractionation combined with immunostaining for neuron-specific nuclear antigen (NeuN) to distinguish neuronal and nonneuronal cells (16) , the different methods giving similar results. Subsequently, ratios ranging 1.3-2.7 have been reported for the grey matter of different regions of the human cerebral cortex, highest in frontal and lowest in primary visual (346) . However, in subcortical white matter, glial cells (mostly oligodendrocytes) vastly outnumber neurons (not including passing axons) with a ratio of 15; in subcortical regions, the glia-to-neuron ratio may be as high as 10, in cerebellum as low as 0.2 (because of the extremely large number of granule cells), and in the brain as a whole ϳ1. These figures are similar in human and non-human primates (16) . The glia-to-neuron ratio increases roughly with the size of the brain, along with a decrease in neuronal density. It varies relatively uniformly with neuronal density across brain regions (cortex, cerebellum, rest of brain) and species of different mammalian orders (primates, scandentia, rodents, insectivores, cetaceans, marsupials, carnivore, afrotherian) according to a power function [in the cerebral cortex across several species, glia-to-neuron number ratio ϭ (neurons per cubic mm) Ϫ1. 256 ; r 2 ϭ 0.9, P Ͻ 0.0001] (162). Interestingly, the average rate of use of glucose per neuron does not vary with neuronal or neuroglial density (162) . But it presumably does vary with neuronal size (larger cells use more glucose). Not only in white matter, but even in grey matter of the human neocortex, oligodendrocytes are the most numerous cell type, with the total number ranging 21-29 billion (10 9 , female-male), while the total number of astrocytes has been estimated to be in the range of ϳ5-8 billion, microglia 1.8 -2.0, and neurons 21-26 (325) . On the other hand, nerve cell elements make up the greater part of the volume of brain tissue. In the neuropil of the grey matter of hippocampus CA1, for example, the glial contribution (mostly astrocyte processes) to the tissue volume was estimated at ϳ6% (274) or 4% (424) in rat, and 5% in human (154) . The percentage of glial volume depends on the region and on the tissue preparation, but rarely exceeds 20.
B. Volume Transmission
The concept of volume transmission, as opposed to wired transmission, matches neuroglial transmission. The concept was introduced by Kjell Fuxe and Luigi Agnati and collaborators (3, 4, 130) to describe the fact that the action of neurotransmitters is not confined to the synapse, because the transmitter can diffuse out of the synaptic cleft to reach receptors on cells at a distance from the site of release. Moreover, transmitters, e.g., monoamines, are often released from axon varicosities that do not form synaptic contacts, but activate receptors after diffusing for a variable distance in the extracellular space. Similarly, transmitters released from neuroglial cells spread through the extracellular space before interacting with receptors, although groups of vesicles in astrocytes have been observed to cluster in front of receptor sites on neurons (30).
Receptors outside the synaptic cleft will be more easily accessible to volume transmission such as by transmitters released from neuroglia, compared with wired transmission by neurotransmitters released into the synaptic cleft from the presynaptic terminal. Interestingly, synaptic and extrasynaptic receptors may cause different responses (189, 265) .
C. Astrocytes
Based on the Golgi stain or staining for glial fibrillary acidic protein (GFAP), astrocytes are known as the "star-shaped" cells in the brain. However, GFAP does not reach out to the most delicate processes. When astrocytes were filled with fluorescent dyes it was evident that they rather have a "bushy" cubic appearance (48, 291), sending out several small processes, some of which contact neurons at synapses (perisynaptic processes) and some blood vessels (perivascular processes) (332) (FIGURE 1). Most synapses, the presynaptic nerve ending and the postsynaptic dendritic part of the neuron, are tightly enwrapped by delicate astrocytic processes (424) . Astrocytes are known to occupy their individual domains in the brain neuropil, i.e., each site in the neuropil is served by a single astrocyte. This means that there is very little overlap (ϳ5%) between processes of neighboring astrocytes (48, 291) . It has been estimated that an astrocyte occupies a volume of ϳ66,000 m 3 (48, 291). As there are ϳ213 synapses/100 m 3 brain tissue (197) , this volume comprises ϳ140,000 synapses. Thus the domain organization of astrocytes may be important for astrocytes as modulators of synaptic transmission. These numerous perisynaptic processes are coupled in series with the perivascular end feet processes, enabling astrocytes to make channels connecting the synaptic environment with the bloodstream. Parallel channels are formed by the extracellular space surrounding the astrocyte processes. In addition, the perivascular astrocyte processes, the perivascular end feet, control transfer of substances to and from the extracellular space at the blood-brain interface.
D. Oligodendrocytes
Like astrocytes, oligodendrocytes extend many processes, but instead of contacting synapses the oligodendrocyte processes contact and wrap around a stretch of axon, forming the myelin sheath (FIGURE 1). The long myelinated tracts of axons are particularly important in the human brain where the large size of the brain requires fast conduction velocity to allow widely spaced areas to communicate with a minimum of delay (439) . The saltatory conduction of myelinated axons, by which the nerve impulse jumps from node to node separated by the internodes formed by the myelinated processes of oligodendrocytes, is therefore essential for the cognitive abilities of the brain (120). Mature myelinating oligodendrocytes are formed from oligodendrocyte precursor cells (OPCs), which can be identified by their expression of the proteoglycan NG2 and are also called polydendrocytes due to their highly branched processes. OPCs are present also in the adult brain, constituting ϳ9 and ϳ3% of the total cell counts in white and grey matter, respectively, and are regulated by synaptic glutamatergic and GABAergic input (124). Like astrocytes, oligodendrocytes are able to respond to changes in the cellular and extracellular environment. By doing so, oligodendrocytes are shown to be highly plastic; they can regulate myelin production according to neuronal activity and regenerate distorted myelin in brain diseases. [From Kettenmann et al. (191) 
E. Microglia
Microglia are the innate immune cells in the brain. In the healthy brain they show a highly branched and ramified morphology (FIGURE 1). Microglia get activated in response to almost any type of brain damage. Once activated microglia are transformed into two major cell types. First, the microglial morphology is changed into an amoeboid form. Second, the amoeboid microglia become active phagocytes, eating cellular debris.
Activated microglia can produce a large variety of cytokines, and they influence the fate of neurons by secreting either pro-or anti-inflammatory mediators. The function of microglia in the healthy brain is rather poorly understood. In the healthy brain the processes of microglia are delicate and highly ramified. The processes are moving in the neuropil in search of activating stimuli. Ramified microglia are dubbed "resting," and in contrast to activated microglia, they do not express various types of surface proteins, such as major histocompatibility complex proteins. Which types of signals make the processes of microglia move is unclear. Moreover, there is no clear understanding of the consequences of microglia-neuron contacts in the healthy brain. Like astrocytes, the processes of each microglia appear to survey a volume of brain tissue that is free of processes from any other microglial cell, occupying distinct nonoverlapping territories in the brain (100, 191, 338).
II. ASTROGLIAL TRANSMISSION
A majority of brain scientists study the properties of neurons, but neurons comprise only half of the cells in the brain (see sect. I). As noted above, until recently it was thought that astrocyte cells played a relatively passive role in the central nervous system. By modulating the content of the extracellular space around synapses, astrocytes can interact with neurons to the extent that this organization was termed the "tripartite synapse" to emphasize the direct participation of astroglia in synaptic signaling, along with the nerve ending and the postsynaptic part of the neuron. For example, astrocytes are endowed with glutamate transporters, which can rapidly take up synaptically released glutamate, and thus contribute to inactivation of the postsynaptic glutamate response (406) . Astrocytes also contain K ϩ channels that flux excess extracellular K ϩ into astrocytes, keeping the K ϩ concentration low around synapses. This is important for avoiding K ϩ -induced depolarization of neurons. In the past few years, however, it has become increasingly clear that signaling between neurons and astrocytes plays a crucial role both in the information processing that the brain carries out, and in pathological conditions.
In this respect it is interesting that astrocytes seem to actively participate in synaptic plasticity (417) and memory formation (151) . Mice transplanted with human glial progenitor cells, which developed into mature astrocytes, showed increased long-term potentiation and better performance on different memory tests compared with mice that received murine glial progenitors (151) . This suggests that human compared with mouse astrocytes are more competent of supporting activity-dependent plasticity and memory formation and raises the intriguing question of whether the difference in higher brain functions between human and rodents can, in part, be ascribed to astrocytes and whether neurons and astrocytes work side by side as equal partners in higher cognitive functions.
A. Neurons Signal to Astrocytes
Astrocytes harbor a series of neurotransmitter receptors, e.g., for glutamate and ATP. In the cerebellum, several lines of evidence suggest that small processes of astroglia contain distinct regions that can each interact with a few synapses. These perisynaptic Bergmann glial processes are equipped with the AMPA type of glutamate receptor (254, 355) . Glutamate released at the parallel fiber-Purkinje cell synapse can directly activate Bergmann glia AMPA receptors (254) , triggering local Ca 2ϩ transients in microdomains of Bergmann glial processes (143) . This signal pathway has been shown to regulate cerebellar motor function (355) . In the cerebral cortex, astrocytes do not express AMPA receptors. Instead, the NMDA type of glutamate receptor is thought to convey synaptic signals to astrocytes (211) . In the hippocampus, astrocytes can respond to neurotransmitters released during synaptic activity by activation of metabotropic glutamate and ATP receptors, which in turn produce an increase in the intracellular Ca 2ϩ concentration (79, 318, 328, 335) . As in the cerebellum, in the hippocampus, localized Ca 2ϩ responses can be elicited in microdomains of astrocytic processes by neuronal activity (93). Also, physiological sensory stimulation causes similar increases in intracellular astrocytic Ca 2ϩ levels in different brain regions (331, 368, 436) . Thus astrocytes are positioned in the brain neuropil to sense local synaptic activity and respond to this by elevations in the intracellular Ca 2ϩ concentration (FIGURE 2). Such local responses can be modulated by arousal via locus coeruleus activation and the ensuing global norepinephrine release from noradrenergic nerve endings onto astrocytic ␣1-adrenergic receptors, increasing astrocytic Ca 2ϩ signaling and thereby the gain of the astrocytic network, enabling the network to respond to local neuronal activity (322) . It has been suggested that the ability of astroglia to act as detector of coincidence between arousal and local activity may contribute to sensory-specific attention shifts (322) .
including in response to neuronal activity. The gliotransmitters comprise, e.g., glutamate, GABA, D-serine, and ATP (11) . There is a debate in the field about how gliotransmitters are released, as dealt with in the following paragraphs. Most groups have found evidence for an exocytotic release mechanism (11), while some groups have found that gliotransmitters are released from astrocytes through channels, such as the Ca 2ϩ -dependent Cl Ϫ channel bestrophin 1 (310), volume-regulated anion channels (194) , connexin/ pannexin (270), or P2X purinergic receptors (102). In addition, lactate has been shown to be released from astrocytes, probably through monocarboxylate transporters (245, 431).
Vesicular transporters
Results from many research groups suggest that gliotransmitter release from astrocytes takes place through regulated exocytosis. For this to happen, astrocytes must contain vesicles (synaptic-like microvesicles, SLMVs), into which gliotransmitters can be packed and stored. Indeed, a vesicular compartment consisting of small (Ͻ50 nm in diameter) and clear vesicles containing glutamate and its vesicular transporters, the VGLUTs, or D-serine has been visualized in astrocytes from the intact brain (33, 37, 253, 295, 296, 386) (FIGURE 2). Cultured astrocytes also contain small (ϳ30 -40 nm) and clear vesicles, which can transport glutamate through VGLUTs (74, 253 ; see also Ref. 384) , as well as transporting D-serine (253) . The molecular identity of the vesicular D-serine transporter is not known.
Although functional live imaging studies have not directly visualized vesicles, they suggest that glutamatergic vesicles are present in astrocytes. From such studies in cultured astrocytes, the size of the vesicles is estimated to vary between ϳ30 -50 nm (43) and Ͼ300 nm (64, 248) . Even VGLUT-positive vesicles of several microns have been found in brain slice astrocytes, but these are produced by stimulating the astrocytes either mechanically or with high glutamate concentrations (184, 326, 445) , suggesting that these vesicles are involved in release of gliotransmitters in pathological conditions. Moreover, localization studies have suggested that the three vesicular glutamate transporters, VGLUT1, VGLUT2, and VGLUT3, as well as the vesicular ATP transporter VNUT are all present in astrocytes. In cultured astrocytes, VGLUT1, VGLUT2, and/or VGLUT3 have been detected by immunohistochemistry (10, 37, 43, 74, 204, 236, 250, 268, 283, 336, 384, 458) and by reverse transcription polymerase chain reaction (RT-PCR) (268) . It has been proposed that cultured cells can express proteins that normally are not expressed in cells in situ. This does not contradict the presence of VGLUTs in astrocytes, as they have all been found to be localized in acutely isolated astrocytes both at the protein level (236, 268, 458) and the mRNA level (458) . In line with this are immunohistochemical results, showing that VGLUT1, VGLUT2, and VGLUT3 are indeed located within delicate perisynaptic astrocytic processes in the intact brain (33, 37, 123, 295, 296, 333, 458) . Interestingly, VGLUT3 has been shown to be upregulated in astrocytes after focal cerebral ischemia (360) . In addition to brain astrocytes, retinal Müller cells have been shown to release glutamate by exocytosis of VGLUT3 containing secretory vesicles (229).
In discordance to the above-mentioned studies, some studies do not find VGLUTs in astrocytes. Using knockout controls for VGLUT1-3 antibodies, one confocal study concludes that none of the VGLUTs is present in astrocytes (222) . In our previous studies (295, 296) , the VGLUT labeling in astrocytes was also controlled for by using VGLUT1 and VGLUT3 knockout tissue. The reasons for discrepancies between the results of the former and the latter studies are obscure. The main difference between the studies is that the first study used another source of VGLUT1 antibodies than that used by us (while both studies used the same source of VGLUT3 antibodies). Second, while Li et al. (222) used GFAP, S100␤, and GLT as astrocyte markers, we used glutamine synthetase. It should be noted that we do observe a clear colocalization signal at the confocal level between GLT and VGLUT1 (V. Gundersen and L. Ormel, unpublished observation), which we interpret as partly being due to the fact that GLT is located in neurons (26, 408) and their nerve terminals (129). Such colocalization was not reported by Li et al. (222) . Third, Li et al. (222) detected VGLUT by analyzing the intensity of the colocalization signal from VGLUTs and the astrocyte marker, while Ormel and co-workers (295, 296) detected VGLUT signals directly within astrocytic processes by analyzing several confocal planes, which spanned through the entire processes of astrocytes.
Moreover, two studies using microarray analysis did not detect RNA transcripts for VGLUTs in isolated astrocytes from the mouse brain (51, 239) . This is in contrast to three previous studies detecting mRNA for VGLUTs in acutely isolated astrocytes by RT-PCR (37, 80, 458). Whether these differences are due to methodological differences, such as in the purity of the isolated samples, or sensitivity of the detection method, is not clear.
Gliotransmitter exocytosis
The presence of VGLUT containing small synaptic-like vesicles is in line with the findings that astrocytes are capable of releasing glutamate from a vesicular compartment by regulated exocytosis. However, it should be noted that, like the vesicular release of glutamate, release through anion channels is Ca 2ϩ dependent as shown for bestrophin 1 (209, 391) and VRACs (1) . Thus demonstrating Ca 2ϩ -dependent release of glutamate from astrocytes is not sufficient to conclude that astrocytes can release glutamate by exocytosis.
Direct detection of glutamate released from astrocytes has mostly been performed in cultured astrocytes. Many such studies are consistent with a vesicular release mechanism of glutamate (19, 35, 36, 37, 55, 56, 70, 98, 141, 166, 177, 185, 236, 250, 268, 319, 412, 446, 457, 458) . These reports not only show that astrocytic glutamate release is Ca 2ϩ dependent, but demonstrate that the glutamate release is sensitive to inhibition of various parts of the exocytotic release machinery in astrocytes. For example, glutamate release was inhibited by the VGLUT inhibitors rose bengal and trypan blue, the vesicular H ϩ -ATPase inhibitor bafilomycin A1, and SNARE protein cleavage by clostridium toxins. However, it has been suggested that because cleavage of SNARE proteins could interfere with insertion of plasma membrane proteins, through which glutamate can be released (see below), the effect of clostridium toxins on glutamate release does not necessarily reflect vesicular release (148) . Therefore, the effect of blocking VGLUTs and the vesicular H ϩ -ATPase is particularly important for concluding that the astrocytic release of glutamate is exocytotic. Direct evidence of D-serine release from vesicles in cultured astrocytes has been given (252) .
In addition, to clear and small vesicles (see above), cultured astrocytes contain dense-core vesicles (54, 343) . Like glutamate, ATP has been shown to be released from cultured astrocytes in a fashion compatible with exocytosis (19) , but unlike glutamate, the release takes place through dense-core vesicles or lysosomes (70, 301, 307, 339, 425, 461) . It should be mentioned that glutamate has also been proposed to be released from lysosomes (223), but that glutamate release seems to be much more prominent from small vesicles (236) . The ATP release from lysosomes was recently reported to be mediated through the vesicular nucleotide transporter, VNUT (301) .
Release of ATP from astrocytes has been reported to modify the activity of neurons and astrocytes in several brain regions (42, 142, 199) .
Nonvesicular gliotransmitter release
Astrocytes possess other mechanisms of releasing gliotransmitters than exocytosis. These mainly comprise membrane proteins, which can route gliotransmitters out of astrocytes. Opening of the hemichannels and purinergic P2X 7 receptors described below is not elicited by an increase in internal Ca 2ϩ (405, 451) , suggesting that when Ca 2ϩ levels rise in the astrocyte these proteins do not mediate gliotransmitter release. Opening of unopposed connexin 43 (Cx43) hemichannels in astrocytes can lead to efflux of glutamate (178, 451) and ATP (13, 73, 183, 387) . Similar conclusions have been drawn for pore-forming purinergic P2X 7 receptors. This receptor type can cause ATP (21, 388) , glutamate (102), and GABA (432) to permeate the plasma membranes of astrocytes. There is conflicting data as to whether Cx43 hemichannels or P2X 7 receptors are the main channels for ATP release from astrocytes. For example, a comparative study by Suadicani et al. (388) found that ATP was released through P2X receptors and not through Cx43 hemichannels, while opposite results were found by Kang et al. (183) . It has been proposed that opening of Cx43 hemichannels occurs only after strong membrane depolarization and that Cx43 hemichannels are closed under resting conditions (71) . This suggests that Cx43 hemichannels are most important as a source of gliotransmitter release under pathological conditions when the astrocytes are depolarized. Both Cx43 hemichannels and P2X 7 receptors are likely to mediate "bulk" efflux of cytosolic small molecular compounds, further suggesting that these ways of gliotransmitter release are more important in pathology than physiology. and release of gliotransmitters in astrocytes, and the effects of gliotransmitters on synaptic activity. Glutamate and ATP are synaptically released from presynaptic nerve terminals. They activate metabotropic glutamate and ATP receptors on nearby astrocytic processes, or AMPA receptors on astroglia (as shown, e.g., in cerebellar Bergmann glia). This receptor activation leads to mobilization of Ca 2ϩ from endoplasmic reticulum (ER). Alternatively, Ca 2ϩ can flux into astrocytes from the extracellular fluid via P2X receptors or TPRA-1 channels. The evidence for external influx of Ca 2ϩ is less solid than for release from internal stores. Increase in the cytosolic Ca 2ϩ concentration is a trigger for exocytotic release of gliotransmitters (e.g., glutamate, D-serine, ATP) or channel-mediated release via bestrophin-1 and VRACs. Gliotransmitters can also be released through Ca 2ϩ -independent opening of P2X7 ATP receptors or Cx43 hemichannels. When released, the gliotransmitters can act on receptors on the presynaptic nerve terminal, or on postsynaptic dendrites.
Adding to the complexity of channel mediated release of gliotransmitters, some studies conclude that pannexin channels are the dominant hemichannel type for ATP release from astroglia (172, 389) . Another study suggests that initial ATP activation of astrocytic P2X 7 receptors triggers subsequent release of ATP through both Cx43 and pannexin 1 (135). Moreover, pannexin 1 is located both in astroglia and neurons (171) , and it is unclear whether astroglial or neuronal pannexins contribute to regulation of neuronal function.
Most of the release studies on Cx43 hemichannels, pannexins, and P2X 7 proteins in gliotransmitter release from astrocytes in the intact brain is still elusive. However, by using a Cx43 hemichannel blocking peptide, evidence was found for a role of unapposed Cx43 hemichannel function in the physiological task of memory consolidation (382) , as well as in neuroprotection against spinal cord injury (290), epileptic excitability (453) , and neonatal ischemia (83, 85). In the retina, the effect on neuronal survival of blocking Cx43 hemichannels during ischemia was largely due to a rescue of endothelial cells (78) . The Cx43 blocking peptides (TATCx43L2 and peptide5) used in the above-mentioned studies are selective for hemichannels, but whether they are isoform selective for the Cx43 protein is not resolved (2, 84, 435) . Other studies suggest that Cx43 is involved in development of different pathological conditions, such as cerebral ischemia (277, 278, 378) and chronic pain (63) . However, as these studies used Cx43 knockout tissue, it is difficult to differentiate between an effect on unopposed hemichannels or gap junctional Cx43.
There is strong evidence for astrocytic release of glutamate through volume-regulated anion channels (VRAC), both from astrocytes in culture and in situ (1, 157, 193, 233, 395, 433) . Like vesicular glutamate release, glutamate release through VRACs is regulated by the intracellular Ca 2ϩ concentration (156, 267) . The question is whether, for example, neuronal activity can induce sufficiently large osmotic changes in astrocytes under physiological conditions to trigger glutamate release through VRACs. In this respect it is interesting that ATP has been shown to potentiate swellinginduced release of glutamate from astrocytes (228, 266, 267) . Hitherto, glutamate release via VRACs has convincingly been demonstrated to take place only under pathological conditions, such as in stroke (116, 460) and spreading depression (23). However, in favor of a physiological role, it has been shown that bradykinin could stimulate VRACmediated release of glutamate under conditions that did not cause visible astrocyte swelling (232) . This was demonstrated for mouse astrocytes in culture, while bradykinin seems to trigger a vesicular release of glutamate from cultured rat astrocytes (177, 268, 313) . Despite the fact that most studies conclude that VRACs mediate astrocytic glutamate release, this is probably not a way to selectively regulate glutamate release from astrocytes. Along with glutamate, several other amino acids, such as aspartate, taurine, and glutamine, are released via the VRACs (193, 395) .
Under physiological conditions, glutamate and GABA could be released via another anion channel, the Ca 2ϩ -activated chloride channel bestrophin-1. First, it was shown that bestrophin-1-mediated GABA release from Bergmann glia underlies tonic inhibition in the cerebellum (218) , and that the degree of tonic inhibition in different brain regions correlates with the concentration of GABA in astrocytes (452) . Then the same group showed that bestrophin-1 could induce release of glutamate from hippocampal astrocytes (444) and that this release led to slow inward NMDA receptor currents in CA1 pyramidal neurons (150) . Immunoelectron microscopy has revealed that bestrophin-1 is present in distal perisynaptic processes of astrocytes (444) . However, bestrophin-1 is not selectively localized in astrocytes, as the protein has been found both in astroglia and neurons in the hippocampus and the cerebellum by in situ hybridization and immunocytochemistry (218) . The role of bestrophin-1 in neurons is not known.
Thus it seems that glutamate can be released from astrocytes by at least two different pathways under physiological conditions: channel-mediated bestrophin-1 release and vesicular release. Whether these release mechanisms operate simultaneously or under different physiological conditions, and which of the pathways are most active, remains to be investigated.
There are no reports on vesicular GABA release from astrocytes. Thus, based on the above-mentioned studies, the main glial release of GABA in the brain seems to occur in the cerebellum, and the mechanism is release through bestrophin-1 situated on Bergmann glia. However, the finding of high levels of GABA specifically in Bergmann glia (452) is not easily reconciled with previously published observations. Immunoperoxidase light microscopy for GABA has shown almost exclusive neuronal staining and no clear sign of labeling of the characteristic radial Bergmann glia in the Purkinje and molecular layer in the cerebellum [see, e.g., Figure 1 , B and D, in Ottersen et al. (297) ]. This suggests that the concentration of GABA in the Bergmann glial cells is rather low. Previous immunogold studies of glutamate in the cerebellum (380) and the hippocampus (46) have shown that the concentration of glutamate is similar in Bergmann glia and hippocampal astrocytes. The glutamate concentration in astroglia in these regions is ϳ20% of that in glutamatergic nerve terminals, suggesting an astroglial glutamate concentration of ϳ2 mM. Bestrophin-1 is a Cl Ϫ channel that is permeable for anions with the following order of permeability: NO 3
. It has been shown that it also fluxes the negatively charged amino acids aspartate and glutamate, in addition to the neutral zwitterion GABA. The relative permeability for these amino acids is lower than for Cl Ϫ [glutamate ϳ0.5 (311), GABA ϳ0.3 (218), aspartate ϳ0.2 (340)], but of the same order of magnitude. Opening of bestrophin-1 in cerebellar Bergmann glia should therefore lead to competitive efflux of all of these amino acids, and most likely to a higher release of glutamate than of GABA. The role of Bergmann glia-derived glutamate and aspartate for neuronal activity in the cerebellum has not yet been addressed. Some of the above-described complex and partly conflicting results in the channel-mediated release of gliotransmitters could be due to the fact that these are all large pores, permitting release of several small molecules, including amino acids. It is also important that there is a large overlap in the specificity of pharmacological blockers of the different channels. For example, hemichannel inhibitors block VRACs, and vice versa (450) . It should also be kept in mind that some of the widely used VRAC antagonists can also block other mechanisms involved in glutamate release from astrocytes. 4-(2-Butyl-6,7-dichloro-2-cyclopentyl-indan-1-on-5-yl)oxobutyric acid (DCPIB), the proposed selective blocker of VRACs, was recently shown to block connexin hemichannels and the glutamate transporter GLT (41). Likewise, 5-nitro-2-(3-phenylpropylamino)benzoic acid (NPPB) inhibits voltage-sensitive Ca 2ϩ currents and intracellular Ca 2ϩ stores (196) . Moreover, NPPB blocks the intermediate-conductance Ca 2ϩ -activated K ϩ current (121) and pannexin-1 channels (243) . The molecular identity of VRACs is still awaiting discovery. Such an identification will allow in-depth studies of these channels, including genetic deletion experiments, thus bringing the VRAC field a major step forward. Moreover, care should be taken when interpreting data from experiments using niflumic acid, which is used to block bestrophin-1 responses. This is because niflumic acid is not selective, but blocks other types of channel, e.g., VRACs (e.g., Ref. 312). In arteries, niflumic acid and NPPB inhibit constriction by a mechanism that is independent of Cl Ϫ channel blockade, possibly blocking Ca 2ϩ -dependent contractile processes (188) . When this is said, the bestrophin-1-mediated glutamate and GABA release studies referred to above also used genetic knockdown of bestrophin-1 to ascertain the selectivity of the release.
Gliotransmitter release regulates neuronal activity
An important question is whether vesicular gliotransmitter release from astrocytes takes place in intact brain tissue and whether this can influence neuronal signaling. Indeed, several reports have concluded that gliotransmitters released from astrocytes can regulate synaptic activity and modulate neuronal plasticity. In hippocampal slices there is evidence that glutamate is released from astrocytes to enhance or depress both excitatory and inhibitory synaptic activity in nearby neurons (8, 93, 114, 117, 179, 182, 235, 279, 280, 281, 328, 329, 361, 433) . Of particular interest is the study by Di Castro et al. (93) showing that basal and "minimal" synaptic transmission can be detected by astrocytes, which respond by fast and highly local increases in Ca 2ϩ concentrations in subdomains of astrocytic processes. This local Ca 2ϩ increase was translated into release of glutamate and enhancement of synaptic transmission (93).
The ability of astrocytic glutamate to modulate synaptic activity is not restricted to the hippocampus. In slices from the olfactory bulb (202) and thalamus (314) , glutamate derived from astroglia has been shown to modulate synaptic plasticity.
Not only astrocytes that are a part of the tripartite synapse can regulate synaptic activity. Astrocytes contacting axons can also release glutamate, which in turn can broaden the action potential and cause elevation in the intraterminal Ca 2ϩ concentration and increased synaptic activity (363) .
In the somatosensory cortex, astrocytes can modulate cortical rhythms by regulating the activities of synaptic NMDA and adenosine A1 receptors, leading to increased excitation and inhibition, respectively (113). Interestingly, cannabinoid signaling also links astrocytic glutamate release and synaptic functions. In the intact brain in vivo, selective activation of the cannabinoid receptor CB1R in astrocytes can mediate astrocytic glutamate release and subsequent LTD and impairments in working memory (149) .
There is growing evidence that astrocytes in the intact hippocampus can also release D-serine, which can act on the glycine site of NMDA receptors and can enhance glutamatergic synaptic plasticity, such as LTP (161, 375, 449) . In the hypothalamus, D-serine released from astrocytes can induce LTP (304) . Interestingly, astrocyte-derived D-serine has been demonstrated to regulate somatosensory cortical plasticity in vivo (396) .
Like glutamate, ATP acts as an excitatory transmitter at brain synapses. In addition to vesicular release from presynaptic nerve terminals (212), ATP is released from astrocytes and is proposed to regulate astrocyte networks by mediating propagation of Ca 2ϩ waves between gap junction-coupled astrocytes (198) . However, astrocytic ATP can also regulate neuronal activity (199) . Using hippocampal slices, Pascual et al. (315) showed that ATP released from astrocytes was rapidly converted to adenosine, which produced a tonic suppression of synaptic activity mediated by A1 adenosine receptors. Likewise, ATP gliotransmission is important for sleep homeostasis through production of adenosine (146) . The depressive effect of purines on synaptic activity was shown to be caused by downregulation of neuronal NMDA receptors, probably through an action on presynaptic A1 receptors (90). Adding to the data showing a physiological role of astrocytic ATP is the recent finding that freshly isolated and in situ cortical astrocytes can release ATP, which acts mainly on postsynaptic P2X 7 ATP receptors to produce a reduction in dendritic GABA A receptors resulting in downregulation of phasic and tonic inhibition (210) . In line with this study is the report (305) that astrocytes in the hippocampus can detect physiological synaptic activity ("minimal synaptic stimulation") by local increases in intracellular Ca 2ϩ . This leads to release of purines that can regulate synaptic transmission through presynaptic A2 purinoceptors. Interestingly, adding to the growing evidence for the role of astrocytes in complex brain functions, astrocytes in the brain stem have been demonstrated to act as chemosensors (142) . They respond to changes in pH by elevations in intracellular Ca 2ϩ , causing ATP release, which in turn activates chemoreceptor neurons, leading to increased breathing (142) .
In all of the above-mentioned studies the release of gliotransmitters is dependent on a rise in the intracellular Ca 2ϩ concentration in astrocytes. The release mechanism of gliotransmitters has been addressed in detail in some of the studies, among others by determining the sensitivity to blocking SNARE proteins. Functional methods, including patch-clamp electrophysiology, have produced substantial evidence for exocytosis of glutamate from astrocytes in intact tissue (114, 179, 329) . Also the release of D-serine from hippocampal astrocytes seems to follow an exocytotic route (161) . This is also true for ATP release from the hippocampus and the cerebral cortex (146, 211, 315) . In contrast, there is also evidence that volume-regulated anion channels mediate efflux of glutamate from hippocampal astrocytes (433) .
From the above discussion it is clear that gliotransmitter release is regulated by various mechanisms and can lead to a wide variety of synaptic responses. Glutamate from astrocytes can enhance synaptic strength by stimulating metabotropic or NMDA type glutamate receptors on presynaptic nerve terminals, causing increased synaptic release of glutamate (117, 179, 329). At inhibitory synapses a similar mechanism seems to enhance GABAergic inhibition; synaptically released GABA stimulates astrocytes to release glutamate, which then acts on presynaptic GABA terminals to increase GABA release (182) . In addition, astrocytic glutamate release can increase neuronal excitability by stimulating NMDA receptors located outside the synaptic specialization on postsynaptic dendrites (9, 77, 114, 314, 328) . This generates slow inward synaptic currents (SICs) through the NMDA receptors, which can contribute regulation of excitability in a large network of neurons. Bear in mind that one astrocyte "overlooks" as many as 14,000 synapses (see sect. I).
These different actions of one single gliotransmitter, such as glutamate, could be related to the brain regions in which it is released. For example, enhancement of synaptic strength is observed in the dentate gyrus, while SICs are mostly found in the stratum radiatum of the hippocampus proper. Also the nature of the intracellular Ca 2ϩ signal in the astrocytes is important for the release probability of gliotransmitters from astrocytes. This is exemplified by the fact that activation of different receptors on astrocytes results in various types of intracellular Ca 2ϩ signals. All of these are not equally capable of stimulating gliotransmitter release, as observed in hippocampal slices, where Ca 2ϩ elevations triggered by activation of PAR-1 receptors, but not P2Y 1 receptors, elicit NMDA receptor mediated SICs (374) . In this respect, it is likely that local Ca 2ϩ elevations in microdomains of astrocytic processes, which contact synapses, modulate the probability of gliotransmitter release, and thus the effect on synaptic function (426 (305) suggest that the astrocytes are activated by mGluR5. These differences could be explained by the fact that the former studies were performed in the dentate gyrus, while the latter used the CA1 region of the hippocampus as a model system. Thus astrocytes in different brain regions could be equipped with different densities of various types of receptor along their processes, and they could use different gliotransmitters to modulate synaptic transmission. The source of the ATP that stimulates astrocytes in the dentate gyrus was not resolved in Di Castro et al. (93) . If ATP is released from astrocytes, this would speak against the possibility that the observed Ca 2ϩ events in astrocytes are a direct consequence of synaptic activity, but it should be kept in mind that ATP is indeed released at glutamatergic synapses in the brain (212, 307a) .
Further contributing to a substantial complexity of the action of gliotransmitters on the neuron-glia network activity is the fact that a single gliotransmitter can have different effects depending on the neuronal element and which receptor subtypes it reaches. For example, glutamate released from astrocytes may cause different effects, depending on whether it interacts with synaptic or extrasynaptic receptors (189), the latter presumably being more easily accessible to astrocyte-derived glutamate. Whereas activation of synaptic NMDA receptors has neuroprotective effects, activation of extrasynaptic NMDA receptors causes neuronal damage via increased neuronal NO and the ensuing nitrosative stress leading to synaptic damage and other mecha-nisms (265) . While the physiological significance of this response remains to be determined, it may help explain the deleterious effect of amyloid-␤ peptide (A␤) on synapses in Alzheimer's disease: oligomeric (but not monomeric) A␤ binds to and stimulates ␣7 nicotinic acetylcholine receptors on astrocytes, which in turn leads to release of glutamate. This astrocytic glutamate activates extrasynaptic NMDA receptors to depress excitatory synapses in hippocampus (397) . This action of A␤ was blocked by the novel, extrasynaptic-selective NMDA receptor antagonist nitromemantine (397), providing promise for treatment, and illustrating the importance of neuroglial transmission.
Another interesting possibility is that molecular heterogeneity of astrocytes can contribute to explaining the different results on mechanisms underlying gliotransmitter release described above. Astrocytes have generally been thought to make up a rather homogeneous population of cells, because they all have similar "passive" electrophysiological properties. However, it is known that astrocytes in the grey matter of different brain regions display different morphologies (106), indicating that these populations have different molecular compositions. Such a phenomenon was first detected in mouse hippocampus, where GFAP expressing astrocytes were divided into seemingly nonoverlapping groups containing either glutamate transporters or AMPAtype ionotrophic glutamate receptors (255) . However, later the "AMPA type" of astrocyte has been identified as OPCs (414) . In human isocortical and hippocampal astrocytes, the plasmalemmal protein and extracellular matrix receptor CD44 is a marker of astrocytes with "fibrous" as opposed to "protoplasmic" morphology, and is correlated with high immunostaining for GFAP, and S100␤, but low immunostaining for glutamine synthetase, and excitatory amino acid transporter 1 (EAAT1), and EAAT2 (381). As discussed above, astrocytes can perform a wide variety of functions. However, whether these diverse functions can be performed by all astrocytes, or are attributes of distinct subpopulations, remains an open question. Only a few experimental approaches have been used to dissect the molecular diversity of astrocytes, e.g., Doyle et al. (101) used a novel RNA detection system (TRAP, BAC transgenic mice, see below) to show that astrocytes isolated from the cortex and the cerebellum have different mRNA sets. However, these studies did not investigate mRNA profiles of astrocytes from several brain regions. Gene expression profiles of astrocytes have been presented (51, 240). While reporting the transcriptome of the whole astrocyte population, these studies did not provide any additional insight into their heterogeneity. Methodological limitations prevent the accurate determination of the astrocytic transcriptome (327).
L-Lactate: transmitter and fuel
Astrocytes are not only sources of release of "classical" gliotransmitters; they can also produce and release lactate, for which there is growing evidence of an action as a volume transmitter in the brain (29). Astroglia make lactate by glycolysis from astrocyte-stored glycogen or from bloodborne glucose. Lactate diffuses down its concentration gradient 1) intracellularly, 2) through the gap junction connected astrocytic network, 3) into the extracellular space through MCTs, 4) extracellularly along glial and neuronal processes, and 5) into adjacent neurons and other cells via MCTs. Through these routes (FIGURE 3) , astrocyte-derived lactate may act as an autocrine mediator on receptors on astrocytes, or as a paracrine mediator on receptors on neurons and other cells at a distance, i.e., as a volume transmitter (29). Similarly, lactate released from neurons could act on lactate receptors on glia as well as neurons. The notion that lactate can travel considerable distances in brain tissue from a point of release is supported by observations on the distribution of microinjected radiolabeled lactate and inulin (75) . As expected, inulin, which is restricted to the extracellular space, spread farther than lactate, which accesses intracellular compartments and is metabolized (1.5 and 2.4 mm, respectively, in 10 min). When lactate is produced from glucose, proton is generated corresponding to the production of lactic acid (271) , which is dissociated to a proton and a lactate anion at physiological pH. The MCTs cotransport lactate with protons, in a facilitative transport process driven by the concentration gradients of protons and lactate (147) . Changes in pH that accompany lactate transients may therefore cause effects in addition to those of the lactate anion. pH is known to affect a wide range of ion channels and receptors (438) , including glutamate receptors (246, 410) . pH even modifies (and is modified by) histone acetylation, thereby influencing gene expression (258) . Lactate is formed from pyruvate through the lactate dehydrogenase reaction, regenerating NAD ϩ to sustain glycolysis, and can undergo the reverse reaction to produce pyruvate and change the NADH-to-NAD ϩ ratio. The extracellular lactate-to-pyruvate ratio reflects the intracellular NADHto-NAD ϩ ratio, although this relation will be perturbed on deviation from equilibrium conditions (390) . Pyruvate as well as redox change can signal through gene control (276), e.g., modifying protein deacetylation by sirtuins (62, 342) . The NADH-to-NAD ϩ ratio also has signaling effects at the protein level. Thus lactate, through increasing the NADHto-NAD ϩ ratio, augments NMDA receptor function, increasing intracellular Ca 2ϩ levels and thereby stimulating the expression of synaptic plasticity-related genes both in vitro and in vivo (447) . The redox ratio and the lactateto-pyruvate ratio form a signaling network (61, 155, 263) contributing to the volume transmitter actions of lactate (29).
Recently, a lactate receptor in the strict sense was discovered to be active in the brain (31, 45, 213) , namely, the G protein-coupled receptor GPR81, also known as hydroxycarboxylic acid receptor 1 (HCA 1 or HCAR1). GPR81 was "deorphanized" by being shown to cause downregulation of cAMP in adipocytes (53, 231) in response to insulininduced lactate production, the released lactate acting as an autocrine messenger mediating the antilipolytic action of insulin (5) . HCAR1 has millimolar affinity for L-lactate, the EC 50 ranging 1-7 mM depending on the assay conditions and the species, and unlike lactate transporters and metabolizing enzymes, has similar affinities for L-lactate (the physiological enantiomer) and D-lactate. The receptor is highly selective for lactate compared with other short-chain fatty acids. In the brain, the extracellular concentration of L-lactate as measured by microdialysis is ϳ1 mM at rest, and when lactate was infused intravenously to reach a blood concentration of ϳ10 mM, the extracellular concentration in the brain was ϳ2 mM (152) . These concentrations are in the dynamic range of the receptor. Importantly, at lactate concentrations below the EC 50 , the effect on the receptor is roughly proportional to the concentration. Agonists with higher affinities and high selectivity towards HCAR1, compared with HCAR2, HCAR3, and other closely related receptors, have been identified, including 3,5-dihydroxybenzoic acid (apparent EC 50 ϳ0.15 mM) (230), its derivative 3-chloro-5-hydroxy benzoic acid (apparent EC 50 ϳ0.02 mM) (104), and the high-affinity "Compound 2," 4-methyl-N-(5-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-4-(2-thienyl)-1,3-thiazol-2-yl)cyclohexanecarboxamide (apparent EC 50 ϳ0.00005 mM) (357) . The availability of high-affinity ligands will facilitate investigations of the physiological and pathophysiological roles of HCAR1 and serve as a basis for developing potentially useful drugs. The fact that hydroxyphenolic acids are constituents of foods, such as vegetables, fruits, and berries, and may activate HCAR1 more strongly than lactate, suggests that natural products from foods could modify lactate receptor transmission. Natural transient changes in the brain extracellular lactate concentration occur during physical exercise (87, 300, 409, 419). The discovery of the lactate receptor in brain invites the hypothesis that intermittent HCAR1 activation mediates some of the beneficial effects of physical exercise on the brain by modifying lactate gliotransmission. The hypotheses that the lactate receptor contributes to effects of nutrients and physical activity on the brain should be tested experimentally.
In rat hippocampus slices, the lactate receptor downregulates forskolin-stimulated cAMP (213) , and in primary cultures of mouse cortex, it downregulates Ca 2ϩ spiking activity in principal neurons as well as in GABAergic neurons (45). These observations indicate that receptor action of lactate can curb excessive neuronal activity, e.g., in a situation of stress where excessive adrenoceptor activation of neurons with ensuing excessive cAMP leading to leaky ryanodine receptors (237) or overstimulation of hyperpolarization-activated cyclic nucleotide-gated (HCN) and KCNQ potassium channels (316, 434) with consequent cognitive dysfunction, could be tempered by lactate produced in response to adrenoceptor activation of astrocytes to produce lactate acting on HCAR1. This is still a hypothesis awaiting testing.
In contrast to such negative regulation, lactate has recently been proposed to mediate positive feedback regulation of norepinephrine release from locus coeruleus neurons: astrocyte delivered lactate caused upregulation of cAMP in these neurons, with relatively high affinity (apparent EC 50 ϳ0.5 mM) and stereospecificity (398) compared with HCAR1. The authors (who did not seem to be aware of the previous work on brain lactate receptors) concluded that the effect must be mediated by a lactate receptor other than HCAR1, due to the higher affinity, different substrate specificity, and opposite effect on cAMP. However, as G protein-coupled receptors act with ligand-dependent bias through variable intracellular messenger systems (345), the action might still involve HCAR1. Recently, HCAR1 has been shown to signal, independently of adenylyl cyclase, through arrestin-␤2, inhibiting tissue damage via innate inflammatatory mechanisms involving Toll-like receptors and the nucleotide binding and oligomerization domain-like receptor family pyrin domain containing 3 (nod-like receptor protein 3, NLRP3) inflammasome (168) , and through a protein kinase C (PKC)-dependent pathway and an IGF-IR transactivationdependent pathway to activate ERK1/2 (224), demonstrating that the result of GPR81/HCAR1 activation is not limited to inhibition of adenylyl cyclase. The effects of lactate through inflammasome inhibition prevented death from experimental hepatitis and pancreatitis (168) , indicating a significant therapeutic potential. These effects were observed after administering lactate intermittently to obtain blood concentrations comparable to those occurring after bouts of moderate to intense physical exercise, suggesting relevance for life-style intervention. Toll-like receptors have complex roles in brain and are implicated in Alzheimer's disease (AD) (413) . Of note, the NLRP3 inflammasome is activated in human mild cognitive impairment and contributes to neuropathology in AD (139, 160, 234) . The possibility of intervention in these disease mechanisms through the lactate receptor opens a new field of research.
As the only cell in the CNS that contains large amounts of glycogen (330) , astrocytes provide an obvious source of lactate. According to the astrocyte-to-neuron lactate shuttle (ANLS) hypothesis, lactate produced by glycolysis, triggered in astrocytes to provide energy for taking up transmitter glutamate from active synapses, is shuttled over to the active neurons (review in Ref. 324 ). Neurons may depend on this lactate for synaptic transmission (nucleus of the solitary tract, Ref. 275 ) and for essential functions such as memory formation (393) . Another observation indicating the involvement of lactate in synaptic plasticity is that the lactate transporter MCT2 as well as postsynaptic density 95 (PSD95) protein and glutamate receptor subunit 2 (GluR2) are enhanced by the synaptic plasticity mediator brain-derived neurotrophic factor (BDNF) (350) .
The ANLS hypothesis is still controversial (reviews in Refs. 94, 97). A contrasting view is that direct uptake of glucose into neurons is substantial both at rest and in activation and that neuronal glucose-derived pyruvate rather than astrocyte-derived lactate is the major oxidative fuel in neurons (321) . Astrocytes account for ϳ30% of the brain oxidative rate (163) , which exceeds (274), although thought similar to (163) , their proportion of the brain volume, indicating at least as high oxidative rates in astrocytes as in neurons. Furthermore, it has been asserted that astrocytes have faster and higher capacity for lactate uptake and dispersal via the astrocytic gap junctional syncytium, compared with shuttling of lactate to neurons from neighboring astrocytes, and can also deliver glucose to neurons (133). Astrocyte mitochondria are retained at sites of intense glutamate uptake induced by neuronal activity, as recently shown in slice cultures of rat hippocampus (175) , supporting the role of oxidative metabolism in astrocytes to provide energy for their Na ϩ -K ϩ -ATPase. In a review, Hertz et al. (163) point out that astrocytes, because of their content of pyruvate carboxylase, can synthesize glutamate (which can be released as gliotransmitter, or funneled to neurons as glutamine). They also point out that astrocytes oxidize glutamate. An advantage of using oxidation of glutamate to fuel glutamate uptake is that substrate is available according to demand and that it spares glucose for use by neurons (96).
The thinnest processes of astrocytes, which enwrap other cells and constitute most of the astrocytes' surface area, have no mitochondria, but do contain glycogen; they depend on glycogenolysis and glycolysis, or intracellular diffusion of high-energy phosphate compounds for energy supply. Mitochondria have been described at branching points of peripheral astrocytic processes (214) , but the pictures (Figure 7 of Ref. 214) show that mitochondria do not occur in the fine juxtasynaptic processes, which are too narrow for larger organelles. The glycolysis in mitochondria-less but glycogen-laden perisynaptic astroglial processes will increase intracellular as well as extracellular lactate levels (lactate exiting through MCTs). However, activated neurons may produce lactate from ambient glucose without glycogenolysis, as illustrated by climbing fiber stimulation of AMPA-type glutamate receptors on cerebellar Purkinje cells. This caused increases in extracellular lactate, postsynaptic currents, blood flow, and glucose and oxygen consumption, which were blocked by blocking AMPA receptors with CNQX, but not by blocking glycogenolysis (50). This observation indicates that lactate exits the activated neurons, rather than entering neurons from astocytes. As the lactate concentration in the dialysate rose by 30% during stimulation (50), considerable local lactate concentration transients must be expected in brain tissue during neuronal activity, providing a basis for dynamic activation of lactate receptors such as HCAR1.
Interestingly, the transient lactate increase in cortex in response to visual stimulation is significantly greater in panic disorder patients compared with controls (244), perhaps indicating that the long-known ability of sodium lactate infusion to provoke panic attacks in susceptible individuals involves an action on lactate receptors. Panic disorder patients have ␤-adrenoceptors with lowered affinity (217) and low cAMP levels (251) (both recorded in blood cells, as proxy for brain), suggesting that cAMP may be disproportionately reduced on activation of HCAR1 by lactate.
Whereas most of the energy consumption in synaptic transmission goes to driving postsynaptic currents (15, 153) , the spines generally lack mitochondria (226, 330). Consistent with this, the complex of glycolytic enzymes is associated with the plasmalemma and endoplasmic reticulum membranes, and ATPases transporting K ϩ , Na ϩ , and Ca 2ϩ use ATP from glycolysis (92). This means that lactate produced in glycolysis must diffuse through the spine neck to the dendrite branch to be oxidized in mitochondria there, or exit the spine through MCT2, conveniently situated at the PSD (32), to be oxidized in other cells. Alternatively, lactate may reenter the spine later, if the concentration gradient reverts upon mitochondrial oxidation, and then diffuse to reach mitochondria in the dendritic branch proximal to the spine. The time required for diffusion of lactate to reach mitochondria may help explain why glucose consumption exceeds oxygen consumption shortly after brain activation (95). It will be interesting to work out the time-lag represented by such translocation of lactate compared with the lag in oxygen consumption. Generation of lactate in the tissue is implicated in the concomitant increase in blood flow (418) . Interestingly, this increase in blood flow without an increase in oxygen consumption is dependent on ␤2-adrenergic receptors and abolished by ␤-adrenoceptor blockers (341, 366) . These observations may represent arousal-triggered ␤-adrenoceptor stimulation of cAMP, enhancing glycolysis (220) . Part of this glycolysis in excess of oxidation would occur in the activated dendritic spines (50), which on activation could form a microdomain of high lactate concentration.
The lactate receptor HCAR1, colocalized with MCT2 at the synaptic spine, and to a lesser extent also on vascular endothelium and astroglia (213), could be activated by the exiting lactate to curb cAMP. As cAMP stimulates glycolysis in brain (220) , this would serve to prevent excessive rates of glycolysis in the spine, one effect of which would be excessive decrease in pH. Low pH is known to inhibit glutamate receptors (247, 273, 410) and affect excitability by modifying Cl Ϫ channels (323) . In astrocytes, high pH causes increased production of cAMP by bicarbonate-sensitive soluble adenylyl cyclase-activated by bicarbonate taken up through the electrogenic NaHCO 3 cotransporter (NBC) after elevation of extracellular potassium, in response to local neural activity, leading to glycolysis with production of lac-tic acid (67) . In addition to counteracting the alkalinization caused by bicarbonate uptake, the ensuing lactate release from astrocytes could act as a gliotransmitter on glial and neuronal HCAR1 to downregulate the elevated cAMP and stabilize pH.
Several observations indicate neuroprotective effects of lactate in conditions such as brain ischemia or brain trauma (40, 76, 369, 370). After traumatic cerebral injury, the brain appears to switch from glucose to lactate as a the main fuel (138) . However, the beneficial effects of lactate are not fully accounted for by metabolism (97); for instance, lactate cannot cause energy production in the absence of oxygen. It now appears probable that actions via the lactate receptor HCAR1 explain these effects, at least in part, as well as resolving controversies over the ANLS hypothesis.
Extracellular lactate, originating in excitatory synapses on spines, or in astrocytic processes, would be able to activate HCAR1 and possibly other lactate receptors, on the spines, or on other structures in the brain tissue, exemplifying volume transmission to and from astrocytes. The selective localization of the lactate transporter MCT2 (32) as well as the lactate receptor HCAR1 (213) at the postsynaptic membrane, and in intracellular compartments, of glutamatergic synaptic spines (FIGURE 3) suggests that lactate forms a hub where synaptic transmission and neuroglial transmission meet.
An example of probable involvement of lactate in such neuron-glia interaction is through BDNF, a factor essential for neural plasticity and learning (216) , and for the beneficial effects of physical exercise on the brain (66, 112, 420) . BDNF is thought to exert autocrine/paracrine action (22, 170) on neurons and is produced by neuronal cells as well as astrocytes in response to stimulation by lactate (69) . Moreover, intravenous infusion of lactate causes BDNF to increase in blood, probably originating in brain (365) . The mechanism of this stimulatory effect of lactate on BDNF remains to be determined, one possibility being that HCAR1 is involved. In exercise, the lactate receptor on neurons and glia could be activated by lactate entering from blood and/or produced by astrocytes in response to catecholamines as outlined below.
In section IIA, we mentioned that the global activation of astrocytes, triggered in arousal through noradrenergic axons from locus coeruleus hitting ␣1-adrenergic receptors on astrocytes to increase Ca 2ϩ signaling in the astroglial network, enhances responses to local neural activity (322) . In parallel, the norepinephrine released will also activate ␤2-adrenergic receptors to increase cAMP and augment glycolysis, powering, inter alia, membrane transport essential for neuronal and glial signaling (see above) (92). Increased astrocytic cAMP will also favor the open mode of gap junctions (108), thereby augmenting spread of solutes, such as lactate, for signaling and support through the astrocytic network. These complementary components of arousal combine to prepare the brain for action. It is intriguing that gliotransmitter lactate from locus coeruleus astrocytes is one of the agents that can elicit the increased locus coeruleus activity to cause general arousal (398) . The subsequent release of gliotransmitter lactate from regional astrocytes in response to elevated cAMP provides a feedback mechanism through HCAR1 to prevent excessive and longlasting rise of cAMP and to tune the cAMP level to fit local and immediate needs. It is becoming increasingly clear that the cellular level of cAMP has an optimum, the apex of the bell-shaped dose-response relationship, that may vary depending on the cell and the conditions (14) . Thus cAMP can have both positive and negative effects in cell physiology and survival (174) . High cAMP can enhance perception in sensory cortex (322) and enhance memory and antidepressant-like effects in the prefrontal cortex (437) , but can impair prefrontal cortex networking required for working memory and higher cognitive functions such as abstract thought and working memory through excessive opening of HCN potassium channels, which are colocalized with cAMP-related proteins in spines at glutamatergic synapses (316, 434) , where also HCAR1 is concentrated (FIGURE 3 ). The observation (352, 441 ) that high-impact exercise (blood lactate Ͼ10 mM) improves memory may be seen in this context: lactate from blood, as well as from astrocytes stimulated by the elevated catecholamines (see above), could act through HCAR1 on spines to temper excessive cAMP levels. cAMP control mechanisms enable flexible modulation of network strength, but when dysregulated, may result in mental disorders, including schizophrenia, bipolar disorder, autism, and age-or stress-dependent cognitive impairment (105, 132), and even neurodegeneration such as in AD (59) . Lactate gliotransmitter signaling via HCAR1, with its widespread distribution in brain regions and in neurons as well as glia (213) , is positioned to contribute to optimizing the local cAMP concentration. It is now important to provide experimental evidence clarifying the extent to which HCAR1 activity contributes to cAMP optimization in different physiological and pathophysiological conditions.
III. OLIGODENDROGLIAL TRANSMISSION

A. Glutamate and GABA
Another novel realm of transmitter action is brain white matter. Fast impulse conduction through white matter tracts is a prerequisite for rapid interactions between spatially separated brain modules and is required to perform higher brain functions. Therefore, the myelination and sustenance of long axons by oligodendrocytes can be assumed to be carefully regulated. Indeed, evidence is accumulating that the action of neuronally released neurotransmitter substances is not limited to astrocytes and microglia (see be-low), but also contributes to the interplay between neurons and oligodendroglia. Indeed, receptors for various neurotransmitters have been immunolocalized on myelinating oligodendrocytes. Both the AMPA type (47, 134, 257) and the NMDA type (186, 261) of glutamate receptor are reported to be present on oligodendrocytes. Activation of NMDA receptors results in an increase in Ca 2ϩ in the myelin sheath, while stimulation of AMPA receptors increases the Ca 2ϩ levels in cell somas (261, 262) . This indicates that NMDA receptor densities are higher in the myelin than in the cell bodies of oligodendrocytes, and that the opposite is true for AMPA receptors. Supporting this, in oligodendrocyte precursor cells during development, NMDA receptors are predominantly located in the myelin sheath, while AMPA receptors are found in the somas (358) .
Glutamate released from synaptic vesicles along unmyelinated axons in the white matter activates AMPA type glutamate receptors on OPCs (206, 462) , suggesting that the role of glutamate is to tell OPCs to myelinate active axons. In line with this, glutamate release is shown (in cultured mouse dorsal ganglion cells) to promote myelin production by inducing the formation of cholesterol-rich domains that mediate membrane interaction between oligodendrocytes and axons, and by enhancing the local synthesis of myelin basic protein (MBP), the major protein in the myelin sheath (428) . Recently it was found that glutamate released from active axons stimulates NMDA receptors on OPCs, which trigger neuregulin-dependent myelination of axons (241) . These actions of glutamate may be the major mechanism by which axonal activity induces myelination; they seem to depend on NMDA receptors (but see De Biase, Ref. 86) rather than AMPA receptors and are mediated through the non-receptor Src family tyrosine kinase Fyn (428, 440) .
Oligodendroglia also signal back to the neuron to sustain neuronal viability in response to neuronal activity. A newly discovered mechanism for this is transfer of exosomes from oligodendrocytes in response to neuronal release of glutamate activating NMDA and AMPA receptors (125). The exosome cargo of proteins and RNA gets taken up by neurons in the mouse brain in vivo, improving neuronal survival in conditions of stress. In addition, oligodendrocytes may improve neuronal function by releasing BDNF in response to activation of metabotropic glutamate receptors (mGluRs) (18) .
However, activation of glutamate receptors on myelin also underlies the vulnerability of myelin to anoxia-ischemia (186) . Thus the ability to tune myelin function to neural function is achieved at the expense of a danger of damage, analogous to synaptic plasticity and learning at the expense of the danger of excitotoxicity.
Compared with neurons and other brain cells, myelinating oligodendrocytes and their precursor cells are particularly vulnerable to energy deprivation (17, 308, 349) (124, 208, 448) . Such direct neuronal control of OPCs persists even in the mature brain (124). It may underlie the experienceinduced changes in myelination, indicated by increased fractional anisotropy observed in the human brain by diffusion tensor magnetic resonance imaging. Such changes have been reported after cognitive and motor training regimes (107, 367, 404, 456) . They are manifested as correlation of interindividual variation in imaging results with cognitive performance during normal development and ageing (144) .
OPCs are excited by neurons releasing glutamate and GABA (34, 136, 186, 187, 206, 207, 227, 462) . Glutamate promotes formation of myelin (241, 428) , while GABA stimulates OPC migration (407) . GABA, like glutamate, may exert its effect extrasynaptically, through volume transmission (421) . Glutamate receptor-mediated inhibition of OPC proliferation (131, 455) may lead to enhanced conduction velocity due to increased internodal lengths when the axons must be covered by a reduced number of oligodendrocytes.
There is evidence that NMDA receptors enhance the differentiation of subventricular zone progenitor cells to oligodendrocytes, through activating PKC (60) . Neuregulin and BDNF, presumably from activated axons (302), switch oligodendrocytes from a myelination mode independent of axonal activity to a mode dependent on NMDA receptors, activated by glutamate released from active axons (241) . A functional interpretation of this is that once myelination has proceeded to a certain level, it may be advantageous to focus the spending of resources on myelinating the axons that are active. BDNF through its receptor TrkB exerts a direct effect on oligodendrocytes, promoting myelination, and an indirect effect on OPCs, regulating their proliferation (443) .
Given the influence of glutamate receptors at multiple functional levels in white matter, they may be involved in a variety of neuropathological conditions. Glutamate function is therefore an obvious therapeutic target in diseases involving white matter (57, 256) . However, white matter is home to glia-glia and glia-neuronal interactions mediated by most of the transmitters operating in grey matter, including glutamatergic, purinergic, GABAergic, glycinergic, adrenergic, cholinergic, dopaminergic, and serotonergic signaling (recent review in Ref. 49).
B. Purines
Neural impulse activity can also influence oligodendroglia by acting through purinergic receptors: ATP and adenosine released from active axons can, in a volume transmitter manner, regulate gene expression, mitosis, differentiation, and myelination of Schwann cells and oligodendrocytes (118, 385) . Both Schwann cells (the peripheral nervous system's counterpart of oligodendroglia) and OPCs have P2 receptors, but while several types of P1 receptors are present in Schwann cells of mice, the OPCs express only A2A and A2BP1 receptors (119). ATP inhibits early Schwann cell differentiation and myelination, whereas adenosine stimulates OPC differentiation and myelination. P2Y 12 purinergic receptors interact physically with a multifunctional extracellular matrix protein, autotaxin, mediating intermediate states of oligodendrocyte adhesion that are crucial for the formation of a functional myelin sheath (91). ATP activates P2X 7 purinergic receptors leading to an inward current and an increase in cytosolic Ca 2ϩ ; during ischemia, ATP is released through pannexin hemichannels to cause damage to oligodendrocytes through these receptors (99). This effect can be overcome by P2X 7 receptor blockers, which can prevent ischemia induced damage of oligodendrocytes and myelin and improve recovery of action potentials (99).
C. L-Lactate
The volume transmitter function of lactate (29) pertains even to white matter. Although a main role of lactate in oligodendrocyte and axon function is as energy fuel and precursor for myelin synthesis (348, 356) , the effects of lactate in white matter likely comprise signaling as well as nutritive support. Lack of energy caused by limited glucose supply inhibits myelination due to impaired accessibility of carbon substrates for the synthesis of myelin lipids (260, 349, 359) . In the presence of oxygen, alternative substrates such as lactate, or N-acetylaspartate (288) , may overcome shortage of energy and biosynthetic precursors.
Once myelin sheaths have formed, the use of lactate by oligodendrocytes apparently changes. Myelin sheaths in adult mice were found to release lactate, which was used by axons (128, 219; commentary in Ref. 347 ). This is consistent with the notion that long axons are supported by lactate from glycolysis in oligodendrocytes (282) . Oligodendrocyte specific knock-down of MCT1 showed that lactate released from the oligodendroglial compartment is crucial for axon integrity and function (219) . The MCT1 knockdown led to abnormal axon morphology and neuronal death in organotypic cultures, which could be rescued by supplying lactate, and caused pathology similar to that seen in patients with amyotrophic lateral sclerosis (ALS) (219) . ALS patients and SOD1 mutant mice (a mouse model for ALS) show reduced MCT1 levels in oligodendrocytes. Deficient supply of lactate from oligodendrocytes might therefore contribute to the pathogenesis of ALS and other neurodegenerative diseases.
The elaborate roles of lactate in myelinated axon tracts call for regulation. It will be interesting to determine to what extent volume transmission via the lactate receptor HCAR1 is involved. An obvious possibility is that HCAR1-mediated downregulation of cAMP in response to lactate (213) reduces energy demand and dampens glycolysis and lipolysis, saving substrates for myelin production. This might underlie some of the beneficial effects of lactate cited in the preceding paragraphs. On the other hand, sustained downregulation of cAMP by HCAR1 activation could be deleterious, since cAMP stimulates vital functions through protein kinase A (PKA) and exchange proteins directly activated by cAMP (EPACs) (7) and can counteract apoptosis (174) . Along this line, chronic cerebral hypoperfusion in the absence of energy deficiency, i.e., without significant reduction in the levels of ATP or phosphocreatine, but with transient elevation of lactate, leads to chronic myelin impairment and astrogliosis in corpus callosum (416) , possibly reflecting receptor actions of lactate.
Roles of lactate in oligodendrocytes and myelinated axons have been reviewed recently (348, 356) .
IV. MICROGLIAL TRANSMISSION
A. Microglia-Neuronal Contacts Affecting Neuronal Function
Most studies on microglia have been focused on their role in the pathological brain. In this review we focus on how microglia interact with neurons in the healthy brain. During the last years it has become increasingly evident that microglia also play distinct roles in the healthy brain. Like astrocytes, until recently microglia in the healthy brain were considered resting or quiescent. However, microglia have been shown to constantly move their processes, surveying the neuropil (81, 284). During this surveillance, microglia are highly active, sending their processes to make dynamic contacts with synapses. These contacts are brief and dependent on neuronal activity (428) . Indeed, through their interaction with neuronal elements, microglia can phagocytose intact synapses, a process that seems to be dependent on activity in neuronal circuits (411) . This suggests that microglia can respond to the functional status of synapses and modulate experience-dependent synaptic plasticity in the healthy brain. Further evidence in support of this idea comes from culture work showing that the presence of microglia increases glutamate signaling in neurons (158, 272) , probably through secretion of neuroactive substances. Moreover, in intact brain tissue lacking the fractalkine receptor, which is predominantly expressed by microglia (264, 286) , there was reduced hippocampal long-term potentiation (351) . However, as fractalkine receptor deficiency triggers activation of microglia (58, 72, 180) , this result does not necessarily reflect physiological regulation of synaptic activity, but could involve indirect effects caused by eliciting secretion of neuroactive substances and cytokines from several types of brain cell (6) .
In line with the results showing that microglia can affect synapses, electron microscopic immunocytochemistry has shown that microglia make contact with synapses (411, 429) . On the basis of these findings, the term quadripartite synapse was coined (25, 351, 364) to also include microglial processes, along with astrocytic processes, and the preand postsynaptic neuronal elements. By immunogold electron microscopy we could show that the delicate microglial processes contacting synapses contained high levels of actin, enabling them to move in the neuropil (379) . Thus the very fine microglial processes are equipped with a motile machinery (FIGURE 4). However, the frequency of synapses receiving direct contacts from surveying microglial processes is rather low at any specific time (379) , suggesting that microglia do not play a major role in physiological regulation of synaptic signaling. Rather, when microglial processes survey the neuropil, they probably stop at synapses that are dysfunctional or inactive, leading to synapse elimination (309, 364, 411) .
B. Microglia Express Neurotransmitter Receptors
The above-described interactions between surveying microglia and neurons are poorly understood. As is the case for astrocytes, microglia are equipped to respond to neuronal activity, through expression of a plethora of receptors for neurotransmitters (137, 191, 334) . So far these studies have mostly been performed in cultured microglia, but some were done in acutely prepared brain slices, using patchclamp electrophysiology to detect microglial responses, or using RT-PCR or immunocytochemistry to detect neurotransmitter receptors in microglia. The AMPA type of glutamate receptor has been shown to be present in cultured microglia (145, 287) , along with metabotropic glutamate receptors: mGluR5 (group I), mGluR2, mGluR3 (group II) and mGluR4, mGluR6, and mGluR8 (group III) (38, 238, 259, 399, 400, 401). There is evidence for the expression NMDA receptors on microglia also in the intact brain, although no in situ electrophysiological data have been given (181) . Microglia in culture express metabotropic GABA B receptors (205) , whereas microglial responses to GABA A receptor activation (284) are thought to be due to indirect effects (65) . Microglial serotonin receptors have also been detected (5-HT 1a , 5-HT 1f , 5-HT 2a , 5-HT 7 serotonin receptors) (203, 371) , along with cholinergic receptors, of which the ␣7 nicotinic type seems to be most prevalent (89, 377), while the presence of muscarinic receptors in microglia has been suggested (165) . Several studies have detected effects of stimulating adrenergic receptors on cultured microglia (127, 337, 422).
Effects of activation of purinergic receptors on microglial function have been quite extensively studied in response to brain injury and will not be dealt with in any detail here (for excellent recent reviews about how purinoceptors regulate microglial motility and phagocytosis under pathological conditions, see Ref. 200 -dependent fashion (392) . Moreover, the ability to respond to purines seems to be a universal property of all microglia, while nonpurinergic transmitters seem to trigger effects in only subpopulations of microglia (191, 371) .
The role of these microglial neurotransmitter receptors is not clear, let alone for the function of surveying microglia in the healthy brain. The molecular composition of the contact points between microglial processes and synapses described above is unknown. Future studies will reveal whether some of the neurotransmitter receptors are concentrated in these sites and whether signal transduction takes place here. It could be that activation of some of the neurotransmitter receptors on microglial processes could contribute to the movement of the processes. For instance, it has been shown that serotonin responses (via 5-HT 2 serotonin receptors) in microglia resulted in increased movement when an insult was given to brain tissue (203) . Whether such enhanced motility is an effect of serotonin receptor stimulation also of surveying microglia, involving increased Ca 2ϩ binding to actin in the processes, is not known. In this respect it is interesting that activation of AMPA receptors could affect polymerization of actin (68) , and thereby contribute to regulation of microglial movement. Again this was found in AMPA receptor-induced amoeboid microglia. Whether it is also true for surveying microglia is not known. Another possibility is that stimulation of the neurotransmitter receptors could help microglia to adapt to different types of activation states. Perhaps microglia can sense neuronal activity through activation of their neurotransmitter receptors, which in turn prevents microglia from being activated. This idea is supported by, e.g., the effect of cholinergic stimulation of microglia, which seems to inhibit their activation (377) . An exception to the anti-inflammatory role of neurotransmitters is glutamate, which when acting on ionotropic AMPA receptors on microglia can trigger activation (377) and release of the pro-inflammatory substance tumor necrosis factor (TNF)-␣ (287). Faced with proinflammatory stimuli, such as TNF-␣, microglia can release glutamate (403) , and thus probably enter a vicious circle with increased generation of glutamate and TNF-␣. However, microglia seems to have developed also a negative-feedback loop, because when glutamate acts on group II and III metabotropic glutamate receptors it attenuates its own release from microglia (259) . In line with this is the finding that activation of group II mGluRs on microglia inhibited degeneration of dopaminergic neurons after exposure to the dopaminergic toxin MPP ϩ , although this effect was ascribed to increased microglial production of BDNF (423) . Complicating this picture are previous data showing that stimulation of group II mGluR on microglia induced microglial activation and resulted in a neurotoxic microglial phenotype.
It is noteworthy that glial cells, through production of TNF-␣, are directly involved in regulation of synaptic function through "synaptic scaling" (383) , which is an overall homeostatic adjustment of synaptic strength of all synapses belonging to a neuron. Whereas TNF-␣ upregulates the strength of excitatory synapses on cortical pyramidal cells by promoting the insertion of AMPA-type glutamate receptors, it promotes the internalization of AMPA receptors in the striatum, downregulating the strength of corticostriatal synapses (221) . There has been a debate about the source of the TNF-␣ in the synaptic scaling process. Both microglia and astrocytes are candidates for such TNF-␣ secretion (383) . In brain inflammation, as a consequence of injury or disease, the secretion of massive amounts of TNF-␣ by activated microglia may transform the physiological actions of the cytokine into harmful ones (362) . Recent findings suggest that TNF-␣ derived from astrocytes rather than from microglia is required for the maintenance of a compensatory increase in excitatory synaptic strength after denervation (24).
Concerning the microglial purinoceptors, their role is found to be important for development and maintenance of a wide variety of brain inflammation processes. The latter is not the topic of the present review and will not be described further here. A comprehensive overview of the function of purinoceptors (as well as of other neurotransmitter receptors) in microglia was given by Kettenmann et al. (191) . However, it should be mentioned that, in particular, the P2X 7 receptor seems to be located on the whole population of microglia throughout the brain (454) , suggesting that this receptor participates in universal microglial processes.
Whether microglia react to lactate via HCAR1 has not been determined, but this seems a likely possibility, considering their kinship with inflammatory cells. Thus macrophages and monocytes in vitro and in vivo react to lactate, which counteracts inflammatory tissue injury by inhibiting Tolllike receptor activation of the NLRP3 inflammasome complex (168). As mentioned above, this effect is mediated by HCAR1 via arrestin-␤2, independent of cAMP, and causes reduced activities of Il1B, Nlrp3, Casp1, NFB, and IL1␤. The same or similar mechanisms are known to operate in microglia and to contribute to inflammatory damage of brain tissue such as occurs in stroke, hemorrhage, trauma, and AD (88, 140, 353, 430) . Intriguingly, activation of microglia (425a) as well as of macrophages (354) causes upregulation of aerobic glycolysis, which results in the production of lactate. Lactate from activated microglia could turn on HCAR1 at adjacent spine synapses and on the microglia themselves, perhaps mediating autocrine feedback inhibition after activation, and could be a useful target for counteracting brain injury of various etiology where inflammation is involved. This hypothesis should soon be tested.
V. CONCLUSIONS
Why neuroglial transmission? Neurotransmission at synapses is high resolution in time and space, on the order of milliseconds and tenths of microns, elicited by an axon action potential. Transmission involving neuroglia can modulate synaptic neurotransmission, based on local conditions in the neural tissue, in many cases integrating over longer times and through tissue volumes that contain many synapses. This provides a mode of regulation complementary to the transmission directly evoked by nerve impulses invading nerve endings. However, astrocytes can respond to synaptic activity by highly local Ca 2ϩ transients, leading to release of gliotransmitters that signal back to synapses within a timescale of seconds. Although no clear synaptic specializations in the contacts between astrocytic processes and synaptic elements have been detected, the distance that the gliotransmitters must diffuse before reaching receptors to act on is probably short and in the micron scale. Such local changes in the intracellular concentration of Ca 2ϩ can probably sum up to give larger transients, spread through the complex astrocytic ramifications to other parts of the cell, and further through gap junctions to other regions of the astrocytic network, the concentration transient declining with the distance. The astrocytic network even communicates with oligodendrocytes via gap junctions. At any point in the network, the triggering of gliotransmitter release will depend on the resultant sum of changes originating in different parts of the surroundings. As a result of this intercellular spread of Ca 2ϩ , a gliotransmitter may be released by Ca 2ϩ -dependent exocytosis in a similar way as neurotransmitters at synapses (e.g., glutamate, ATP, D-serine), or through plasma membrane transporters or channels (e.g., lactate through MCTs, or glutamate and GABA through bestrophin 1). Once released, the transmitter may diffuse through the extracellular space to reach receptor sites at short or long distance, as referred to by the term volume transmission.
A major controversy has been whether gliotransmitters are released through exocytosis of synaptic like microvesicles in glia. Conflicting findings may be ascribed to the use of different experimental conditions. It now appears that both exocytotic and nonvesicular release of gliotransmitters occurs. The challenge for the future is to delineate under which circumstances the different modes of release predominate.
The idea has recently emerged that lactate, a product of brain metabolism, functions as a gliotransmitter. It may act through one or more lactate receptor proteins, as well as through affecting local pH and redox state in central nervous system tissue. The receptor actions of lactate may help resolve controversies over which cells are more important for lactate production, and how lactate counteracts brain tissue damage in cerebral stroke and mechanical trauma. Beneficial effects of physical exercise on brain health may partly depend on lactate from active muscles entering the brain to act on elements of the gliotransmitter mechanisms of lactate, which may be further enhanced by lactate released from astrocytes activated by neurons during exercise.
Surveying microglia in the healthy brain have recently been discovered to enter into contact with neuronal synapses and to have receptors for neurotransmitters/gliotransmitters. Through these, microglia may detect to what extent synapses are active and potentially contribute to elimination of nonactive ones. Future studies will reveal the functional consequences of activation of neurotransmitter receptors in surveying microglia, and whether there are subpopulations of microglia with different expression of neurotransmitter receptors. A major future undertaking will be to determine whether different brain regions are populated by different subtypes of microglia.
Major questions outstanding are the exact roles of neuroglial transmission for normal brain function, and how and to what extent pathological changes in neuroglial transmission contribute to disease processes. The increased understanding to be gained from answering these questions can be expected to impact importantly on managing brain disease.
NOTE ADDED IN PROOF
An important new facet of the gliotransmitter role of lactate is revealed in the just published report by Sotelo-Hitschfeld et al. (381a) . With the use of novel genetically encoded fluorescence nanosensors, these authors show that astrocytes at rest maintain a cytosolic lactate pool in excess of the thermodynamic equilibrium through MCTs, due to the presence of a lactate-permeable anion channel. In response to increased extracellular K ϩ and depolarization of the glial plasma membrane during neural activity, this channel opens to release lactate in a manner enhanced by lactate itself, providing a means for rapid and focused stimulation of lactate receptors such as HCAR1. 
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